Journal Mobile Options
Table of Contents
Vol. 7, No. 1-3, 2010
Issue release date: April 2010
Section title: Imaging, Biomarkers, Genetics and Diagnostic Markers
Free Access
Neurodegenerative Dis 2010;7:139–142

Inability of Plasma and Urine F2A-Isoprostane Levels to Differentiate Mild Cognitive Impairment from Alzheimer’s Disease

Mufson E.J.a · Leurgans S.b
aDepartment of Neurological Sciences, and bRush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Ill., USA
email Corresponding Author

Prof. Elliott J. Mufson, PhD

Rush University Medical Center

1735 W. Harrison Street, Suite 300

Chicago, IL 60612 (USA)

Tel. +1 312 563 3558, Fax +1 312 563 3571, E-Mail


  1. Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ: Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol 2006;65:592–601.
  2. Praticò D, MY Lee V, Trojanowski JQ, Rokach J, Fitzgerald GA: Increased F2-isoprostanes in Alzheimer’s disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998;12:1777–1783.
  3. Praticò D, Iuliano L, Amerio G, Tang LX, Rokach J, Sabatino G, Violi F: Down’s syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 2000;48:795–798.
  4. Praticò D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ: Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002;59:972–976.
  5. Praticò D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA: Increased 8,12-iso-iPF2alpha-VI in Alzheimer’s disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000;48:809–812.
  6. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD: F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 2005;7:269–275.
  7. Irizarry MC, Yao Y, Hyman BT, Growdon JH, Praticò D: Plasma F2A isoprostane levels in Alzheimer’s and Parkinson’s disease. Neurodegener Dis 2007;4:403–405.
  8. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL: Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008;71:85–92.
  9. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J: Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198–205.
  10. Mirra SS, Heyman A, McKeel D Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The consortium to establish a registry for Alzheimer’s disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479–486.
  11. National Institute on Aging and Reagan Institute working group on diagnosis criteria for the neuropathological assessment of Alzheimer’s disease: consensus recommendations for the postmortem diagnosis of AD. Neurobiol Aging 1997;18:S1–S2.
  12. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
  13. Forman MS, Mufson EJ, Leurgans S, Praticò D, Joyce S, Leight S, Lee VM, Trojanowski JQ: Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology 2007;68:757–763.
  14. Kirkwood TB: Geometric mean and measures of dispersion. Biometrics 1979;35:908–909.
  15. Feillet-Coudray C, Tourtauchaux R, Niculescu M, Rock E, Tauveron I, Alexandre-Gouabau MC, Rayssiguier Y, Jalenques I, Mazur A: Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer’s disease. Free Radic Biol Med 1999;27:463–469.
  16. Basu S, Helmersson J: Factors regulating isoprostane formation in vivo. Antioxid Redox Signal 2005;7:221–235.
  17. Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ 2nd, Morrow JD: The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer’s disease patients. Am J Pathol 1999;155:863–868.
  18. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, Terry E, Roberts LJ 2nd, Kaye JA, Morrow JD: Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer’s disease. Ann Neurol 2002;52:175–179.